scholarly journals Efficacy of Multimodal Pain Control Protocol in the Setting of Total Hip Arthroplasty

2009 ◽  
Vol 1 (3) ◽  
pp. 155 ◽  
Author(s):  
Kyung-Jae Lee ◽  
Byung-Woo Min ◽  
Ki-Cheor Bae ◽  
Chul-Hyun Cho ◽  
Doo-Hyun Kwon
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Control Protocol ◽  
Total Hip ◽  
Multimodal Pain Control

Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty

2009 ◽  
Vol 91 (1) ◽  
pp. 29-37 ◽  
Author(s):  
Joseph Marino ◽  
Joseph Russo ◽  
Maureen Kenny ◽  
Robert Herenstein ◽  
Elayne Livote ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Lumbar Plexus ◽  
Postoperative Pain Control ◽  
Total Hip ◽  
Lumbar Plexus Block ◽  
Plexus Block

scholarly journals Evaluation of Intraoperative, Local Site Injections of Liposomal Bupivacaine as an Alternative to Standard Local Anesthetics in Patients Undergoing Total Hip Arthroplasty

2019 ◽  
Vol 55 (4) ◽  
pp. 273-278
Author(s):  
Edward C. Rainville ◽  
Carl Asche ◽  
Jinma Ren ◽  
MinChul Kim ◽  
Lucas Walker ◽  
...  
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Local Anesthetics ◽  
Pain Control ◽  
Opioid Use ◽  
Liposomal Bupivacaine ◽  
Total Hip ◽  
Discharge Disposition ◽  
Successful Recovery ◽  
Hospitalization Costs

Background: Achieving postsurgical pain control after total hip arthroplasty (THA) is a critical factor for successful recovery because inadequately treated pain may lead to a delay in ambulation and hospital discharge and have an adverse impact on a patient’s quality of life. Objective: This study compares the effectiveness of immediate-release local anesthetics for pain control in THA vs liposomal bupivacaine (LB) related to patient outcomes and costs of care. Methods: This is a retrospective cohort study of consecutive patients undergoing THA at 3 hospitals from January 2013 to July 2016. The control group received plain bupivacaine or ropivacaine while the study group received LB. Generalized linear models were used controlling for several patient factors. Primary measures included length of stay (LOS), hospitalization costs, pain relief, opioid use, and mobility. Secondary outcomes were discharge disposition and 30-, 60-, and 90-day readmissions. Results: One hundred and ninety-six patients were identified, with 103 as controls, 70 receiving LB, and 23 excluded. The LB group showed a decrease in LOS of 0.5 days (2.5 ± 2.6 vs 3.0 ± 2.1 days, P = .010), increased mobility on the day of surgery (27.6 ± 49.3 vs 12.5 ± 48.5 feet, P = .001) and the first day after surgery (186.8 ± 133.8 vs 155.2 ± 135.6, P = .039), and decreased hospital costs ($10 670 vs $11 351, P = .022). There were no significant differences in pain scores, opioid use, adverse events, discharge disposition, or readmissions. Study limitations include retrospective analysis, unblinded participants, and generalizability of results. Conclusions: LB provides an effective alternative to standard local anesthetics in patients undergoing THA based on improvements of inpatient parameters, LOS, and cost measures.

Peri-articular injection of an analgesic mixture in primary total hip arthroplasty: an effective strategy for pain control during the first post-operative day

2018 ◽  
Vol 42 (8) ◽  
pp. 1803-1810 ◽  
Author(s):  
Maria Bautista ◽  
Meilyn Muskus ◽  
Adolfo Llinás ◽  
Guillermo Bonilla ◽  
Carlos Guerrero ◽  
...  
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Effective Strategy ◽  
Total Hip ◽  
Primary Total Hip Arthroplasty

scholarly journals Liposomal bupivacaine versus traditional bupivacaine for pain control after total hip arthroplasty

Medicine ◽  
2017 ◽  
Vol 96 (25) ◽  
pp. e7190 ◽  
Author(s):  
Ting-Ting Ma ◽  
Yu-Hui Wang ◽  
Yun-Feng Jiang ◽  
Cong-Bin Peng ◽  
Chao Yan ◽  
...  
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Liposomal Bupivacaine ◽  
Total Hip

Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty

2016 ◽  
Vol 31 (7) ◽  
pp. 1510-1515 ◽  
Author(s):  
Stephen W. Yu ◽  
Alessandra L. Szulc ◽  
Sharon L. Walton ◽  
Roy I. Davidovitch ◽  
Joseph A. Bosco ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Postoperative Pain Control ◽  
Liposomal Bupivacaine ◽  
Total Hip

Forty-eight Hours of Postoperative Pain Relief after Total Hip Arthroplasty with a Novel, Extended-Release Epidural Morphine Formulation

2005 ◽  
Vol 102 (5) ◽  
pp. 1014-1022 ◽  
Author(s):  
Eugene R. Viscusi ◽  
Gavin Martin ◽  
Craig T. Hartrick ◽  
Neil Singla ◽  
Garen Manvelian ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Pain Relief ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Pain Control ◽  
Epidural Morphine ◽  
Extended Release ◽  
Postoperative Pain Relief ◽  
Patient Controlled Analgesia ◽  
Total Hip

Background Epidural morphine has proven analgesic efficacy in the postoperative period and is widely used. This study evaluated the efficacy of extended-release epidural morphine (EREM; DepoDur; Endo Pharmaceuticals Inc., Chadds Ford, PA; SkyePharma, Inc., San Diego, CA) in providing pain relief for 48 h after surgery. Methods Patients (n = 200) scheduled to undergo total hip arthroplasty were randomized to receive a single dose of 15, 20, or 25 mg EREM or placebo. After surgery and after asking for pain medication, patients had access to intravenous patient-controlled analgesia fentanyl for breakthrough pain as needed. Postoperative intravenous patient-controlled analgesia fentanyl use, time to first postoperative fentanyl use, pain intensity at rest and with activity, patient and surgeon ratings of pain control, and adverse events were recorded. Results All EREM dosages reduced the mean (+/- SD) fentanyl use versus placebo (510 +/- 708 vs. 2,091 +/- 1,803 microg; P < 0.0001) and delayed the median time to first dose of fentanyl (21.3 vs. 3.6 h; P < 0.0001). All EREM groups had significantly improved pain control at rest through 48 h postdose (area under the curve [0-48 h]) compared with placebo (P < 0.0005). More EREM-treated patients rated their pain control as good or very good compared with placebo (at 24 h: 90 vs. 65%, P < 0.0001; at 48 h: 83 vs. 67%, P < 0.05). No supplemental analgesia was needed in 25% of EREM-treated patients and 2% of placebo-treated patients at 48 h (P < 0.05). The safety profile of EREM was consistent with that of other epidurally administered opioid analgesics. Conclusions EREM provided significant postoperative pain relief over a 48-h period after hip surgery, without the need for indwelling epidural catheters.

Sign in / Sign up

Export Citation Format

Share Document